Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Evolocumab (Repatha) vs Icosapent Ethyl (Vascepa): Evolocumab (Repatha) has the stronger overall evidence (4.5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Evolocumab (Repatha) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Evolocumab (Repatha) and Icosapent Ethyl (Vascepa) have evidence — compare verdict strength side-by-side.
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.
with-meals
Oral capsule — purified EPA ethyl ester (icosapent ethyl)
Weeks
Months to years
Weeks
Throughout use
Months to years
Weeks
Weeks to months
Throughout use
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
The New England journal of medicine (2019) · Rct · n=8179
REDUCE-IT: 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Journal of the American College of Cardiology (2019) · Rct · n=8179
REDUCE-IT secondary analysis of total (first plus recurrent) ischemic events
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the MARINE trial).
The American journal of cardiology (2011) · Rct
MARINE: randomized, placebo-controlled trial in patients with very high triglycerides (≥500 mg/dL)
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 4.2/10) and wins in 2 of 3 categories.
For support heart health, Evolocumab (Repatha) has a higher relevance score (80 vs 72).
No known interactions between Evolocumab (Repatha) and Icosapent Ethyl (Vascepa) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.